Moxie Clinical
Private Company
Total funding raised: $3.2M
Overview
Moxie Clinical is a San Francisco-based, private CRO founded in 2018, targeting the specific challenges of emerging biotech and MedTech sponsors. Its business model is service-based, offering flexible support from strategic consulting to full-scale trial management, enhanced by a proprietary technology platform utilizing AI and decentralized trial tools. The company positions itself as a strategic, integrated partner rather than just a service vendor, aiming to reduce trial errors, timelines, and costs for its clients in therapeutic areas like neurology, ophthalmology, and cardiovascular disease.
Technology Platform
Integrated platform utilizing AI-powered analytics for trial optimization and monitoring, decentralized trial (DCT) capabilities for patient-centric studies, and risk-based monitoring (RBM) methodologies.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes against large, full-service CROs (e.g., IQVIA, Parexel, PPD) and a crowded field of boutique CROs. Differentiates through its stated 'sponsor-born' perspective, integrated partnership model, and a focused value proposition combining boutique service with advanced trial technology.